PhoenixBio Co., Ltd. (6190.T)

JPY 335.0

(-1.76%)

Market Cap (In JPY)

1.35 Billion

Revenue (In JPY)

1.71 Billion

Net Income (In JPY)

26.37 Million

Avg. Volume

9591.00

Currency
JPY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
325.0-580.0
PE
-
EPS
-
Beta Value
0.331
ISIN
JP3803010002
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Takashi Shimada
Employee Count
-
Website
https://www.phoenixbio.co.jp
Ipo Date
2016-03-18
Details
PhoenixBio Co., Ltd. provides contract study services for drug discovery and development primarily in Japan. The company uses PXB-mouse, a chimeric mouse with a humanized liver for use in drug development experiments; and in vitro studies using fresh human hepatocytes taken from PXB-cells. The chimeric mouse model with a humanized liver is used for in vivo studies in gene therapeutics, NASH/NAFLD drug development programs, anti-viral therapeutic tests, DMPK/toxicity studies, and custom transplantations. The company was founded in 2002 and is headquartered in Higashihiroshima, Japan.